| Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid Y Liu, Y Pang, B Zhu, O Uher, V Caisova, TT Huynh, D Taieb, ... Clinical Cancer Research 26 (14), 3868-3880, 2020 | 38 | 2020 |
| The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands … V Caisova, L Li, G Gupta, I Jochmanova, A Jha, O Uher, TT Huynh, ... Cancers 11 (5), 654, 2019 | 36 | 2019 |
| Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis V Caisová, O Uher, P Nedbalová, I Jochmanová, K Kvardová, ... International Immunopharmacology 59, 86-96, 2018 | 36 | 2018 |
| Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma K Hadrava Vanova, Y Pang, L Krobova, M Kraus, Z Nahacka, ... JNCI: Journal of the National Cancer Institute 114 (1), 130-138, 2022 | 31 | 2022 |
| Coley's immunotherapy revived: innate immunity as a link in priming cancer cells for an attack by adaptive immunity O Uher, V Caisova, P Hansen, J Kopecky, J Chmelar, Z Zhuang, J Zenka, ... Seminars in oncology 46 (4-5), 385-392, 2019 | 23 | 2019 |
| Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis S Ghosal, K Hadrava Vanova, O Uher, S Das, M Patel, L Meuter, ... Endocrine 79 (1), 171-179, 2023 | 18 | 2023 |
| Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan‐BAM, TLR Ligands, and Anti‐CD40 Antibody (MBTA) R Medina, H Wang, V Caisová, J Cui, IH Indig, O Uher, J Ye, A Nwankwo, ... Advanced Therapeutics, 2000044, 2020 | 17 | 2020 |
| Identification of immune cell infiltration in murine pheochromocytoma during combined mannan-BAM, TLR ligand, and anti-CD40 antibody-based immunotherapy O Uher, TT Huynh, B Zhu, LA Horn, V Caisova, K Hadrava Vanova, ... Cancers 13 (16), 3942, 2021 | 10 | 2021 |
| The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives O Uher, K Hadrava Vanova, D Taïeb, B Calsina, M Robledo, ... Endocrine Reviews 45 (4), 521-552, 2024 | 8 | 2024 |
| PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma KH Vanova, O Uher, L Meuter, S Ghosal, S Talvacchio, M Patel, J Neuzil, ... Frontiers in Oncology 12, 2022 | 8 | 2022 |
| rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses J Ye, H Wang, R Medina, S Chakraborty, M Sun, A Valenzuela, X Sang, ... Journal of Experimental & Clinical Cancer Research 42 (1), 163, 2023 | 7 | 2023 |
| Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations O Uher, V Caisova, L Padoukova, K Kvardova, K Masakova, R Lencova, ... Cancer Immunology, Immunotherapy 70, 3303-3312, 2021 | 6 | 2021 |
| rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells H Wang, R Medina, J Ye, Y Zhang, S Chakraborty, A Valenzuela, O Uher, ... Advanced Science 11 (14), 2308280, 2024 | 4 | 2024 |
| Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy O Uher, K Hadrava Vanova, R Lencova, A Frejlachova, H Wang, ... Frontiers in Endocrinology 14, 1030412, 2023 | 4 | 2023 |
| The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma A Frejlachova, R Lencova, A Venhauerova, M Skalickova, O Uher, ... International immunopharmacology 118, 110150, 2023 | 3 | 2023 |
| Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma H Alkaissi, MA Nazari, K Hadrava Vanova, O Uher, CM Gordon, ... New England Journal of Medicine 391 (16), 1552-1555, 2024 | 1 | 2024 |
| PSAT089 lack of effect of metformin in murine pheochromocytoma model HK Ghayee, KH Vanova, K Pacak, O Uher Journal of the Endocrine Society 6 (Suppl 1), A116, 2022 | 1 | 2022 |
| Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma KH Vanova, Y Pang, L Krobova, M Kraus, Z Nahacka, S Boukalova, ... Journal of the Endocrine Society 5 (Supplement_1), A168-A169, 2021 | 1 | 2021 |
| Immu-23. Targeting Metastatic And CNS Tumors Via Mannan-Bam, TLR Ligands and Anti-Cd40 Antibody H Wang, R Medina, V Caisova, O Uher, J Zenka, K Pacak, Z Zhuang Neuro-oncology 21 (Suppl 6), vi123, 2019 | 1 | 2019 |
| Neoadjuvant intratumoral MBT (A) immunotherapy prevents distant metastases and recurrence in murine models O Uher, KH Vanova, R Labitt, K Petrlakova, J Ye, H Wang, M Masarik, ... Cancer Letters 612, 217464, 2025 | | 2025 |
Karel PacakZweryfikowany adres z mail.nih.gov